Ayad M Al-Katib

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status
    Ayad M Al-Katib
    Department of Internal Medicine, Division of Hematology Oncology, Wayne State University School of Medicine, Detroit, Michigan, USA
    J Hematol Oncol 2:8. 2009
  2. ncbi Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma
    Ayad M Al-Katib
    Lymphoma Research Laboratory, Wayne State University School of Medicine, Detroit, Michigan 48202, USA
    Clin Cancer Res 15:4038-45. 2009
  3. ncbi 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity
    Edith J Mensah-Osman
    Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Mol Cancer Ther 1:1321-6. 2002
  4. ncbi An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
    Ramzi M Mohammad
    Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, 732 HWCRC, 4100 John R Street, Detroit, Michigan 48201, USA
    Mol Cancer 8:115. 2009
  5. ncbi Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model
    Edith J Mensah-Osman
    Division of Hematology and Oncology, Department of Internal Medicine and Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Clin Cancer Res 9:5794-7. 2003
  6. ncbi 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model
    Edith J Mensah-Osman
    Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute at Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Mol Cancer Ther 1:1315-20. 2002
  7. ncbi The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia
    Ayad M Al-Katib
    Lymphoma Research Laboratory, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Semin Oncol 30:313-7. 2003
  8. ncbi Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia
    Frances W J Beck
    Wayne State University School of Medicine, 22324 Louis M Ellman Building, 421 E Canfield, Detroit, MI 48201, USA
    Int J Mol Med 14:113-9. 2004
  9. ncbi Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage
    Sanaa M Nabha
    Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Clin Cancer Res 8:2735-41. 2002

Collaborators

Detail Information

Publications9

  1. ncbi SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status
    Ayad M Al-Katib
    Department of Internal Medicine, Division of Hematology Oncology, Wayne State University School of Medicine, Detroit, Michigan, USA
    J Hematol Oncol 2:8. 2009
    ..These findings indicate activity of TW-37 across the spectrum of human B-cell tumors and support the concept of targeting the Bcl-2 system as a therapeutic strategy regardless of the stage of B-cell differentiation...
  2. ncbi Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma
    Ayad M Al-Katib
    Lymphoma Research Laboratory, Wayne State University School of Medicine, Detroit, Michigan 48202, USA
    Clin Cancer Res 15:4038-45. 2009
    ....
  3. ncbi 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity
    Edith J Mensah-Osman
    Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Mol Cancer Ther 1:1321-6. 2002
    ..From this study, we concluded that XK469 up-regulates Topo IIalpha levels and consequently sensitizes indolent malignant B cells to the cytotoxic effect of VP16 in a schedule-dependent manner...
  4. ncbi An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
    Ramzi M Mohammad
    Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, 732 HWCRC, 4100 John R Street, Detroit, Michigan 48201, USA
    Mol Cancer 8:115. 2009
    ..For comparison purpose, MI-319, MI-219 and Nutlin-3 were assessed side by side against FSCCL and three other B-cell hematological tumor cell lines in growth inhibition and gene expression profiling experiments...
  5. ncbi Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model
    Edith J Mensah-Osman
    Division of Hematology and Oncology, Department of Internal Medicine and Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Clin Cancer Res 9:5794-7. 2003
    ..The study supports our in vitro observation that XK469 potentiates VP-16 activity. The sequential use of both agents resulted in clinically significant antitumor activity in the WM model...
  6. ncbi 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model
    Edith J Mensah-Osman
    Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute at Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Mol Cancer Ther 1:1315-20. 2002
    ..We conclude that Topo IIbeta inhibition by XK469 as a target is not sufficient for therapeutic effects in WSU-WM...
  7. ncbi The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia
    Ayad M Al-Katib
    Lymphoma Research Laboratory, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Semin Oncol 30:313-7. 2003
    ..It is, therefore, a particularly useful tool in developing new therapeutic strategies for the more aggressive WM, including targeted therapy, which exploits unique molecular characteristics of tumor cells...
  8. ncbi Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia
    Frances W J Beck
    Wayne State University School of Medicine, 22324 Louis M Ellman Building, 421 E Canfield, Detroit, MI 48201, USA
    Int J Mol Med 14:113-9. 2004
    ..Additional CLL patients under bryo-2-CdA therapy are needed to verify these important observations...
  9. ncbi Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage
    Sanaa M Nabha
    Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Clin Cancer Res 8:2735-41. 2002
    ..The two mechanisms of cell death, i.e., mitotic catastrophe and apoptosis, are independent of each other in our model...